Top Tweets for #LBCl
1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO
Learn More About ALPHA3: https://t.co/QPjgvdVrxs
New @BloodAdvances data show 14% of #LBCL patients die after starting 1L treatment. In 2L, just 15% receive #CAR T. With 75% treated in community settings, structural barriers limit access. The #ALPHA3 trial aims to bring allogenenic CAR T closer to patients. $ALLO #oncology
Learn More About ALPHA3: https://t.co/pYNVYhlyEg
@Eric_Lewin Dans le cadre de l’Accord Servier, #Cellectis est éligible à percevoir jusqu’à 340 millions de $ au titre des paiements d’étapes liés au développement & aux ventes, ainsi que des redevances à 2 chiffres sur CD19, y compris #Cema_Cel développé dans le #LBCL
https://t.co/KwmJCUyxnf
ICYMI: @KatieCouric offered a powerful look at where #CART may be headed next - including off-the-shelf approaches and MRD testing being studied to reduce wait time, expand access, and bring care closer to home for people with #LBCL. #celltherapy #allogeneic $ALLO
Read More: https://t.co/Gd2rkZgoOn
@LydiaSC95640462 L'essai #ALPHA3 par #Allogene qui évalue le traitement #Cema_Cel, issu de la technologie #TALEN de #Cellectis, qui est éligible à percevoir jusqu’à 340 millions $, ainsi que des redevances à deux chiffres sur les ventes de cema-cel développé dans le #LBCL
https://t.co/pheQnMkO9E
Un nouveau chapitre des traitements contre les #CancersDuSang 🩸
Pour les patients atteints de #LBCL agressive, une immunothérapie révolutionnaire transforme les perspectives des patients
Pour plus d'informations sur #ALPHA3 ou trouver un centre d'essai
https://t.co/dIJD82Wpkd
The next chapter of #CART is coming into focus. @KatieCouric highlights how off-the-shelf approaches and MRD testing are being studied to reduce wait time, expand access, and bring care closer to home for people with #LBCL. #CellTherapy #Allogeneic $ALLO
Read more: https://t.co/GbGyeSDUjd
Suite à l'examen de l'analyse d'inutilité intermédiaire, la #FDA 🇺🇸 a accordé les désignations #RMAT et #FastTrack 🚀 à #Cema_Cel 🧬 by #Cellectis $CLLS 🇺🇸 $ALCLS 🇫🇷, soulignant ainsi le besoin non satisfait de la positivité à la #MRD dans le #LBCL 🩸
We are pleased to report our Q2 2026 corporate update and business highlights. #CART #allogeneic #celltherapy $ALLO
Learn more: https://t.co/w7p2NubBwQ
A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhlyEg
1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
Another important milestone – and further momentum for cema-cel. We are pleased to announce that the FDA has granted RMAT and Fast Track designations to our investigational, off-the-shelf #allogeneic #CART product for the treatment of #LBCL.
#celltherapy $ALLO
Learn more: https://t.co/XZZ605ZCba
Real-world PFS after CAR T-cell therapy for R/R LBCL in Japan has improved in the recent era despite expanded treatment indications. Read the full article in Blood Advances: https://t.co/mjgIYzmQFy #BloodAvances #Japan #LBCL
A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
النجمة اللبنانية العربية #نادين_نسيب_نجيم ضيفة الإعلامي المميز #محمد_قيس في بودكاست #قصتي قريباً عبر منصة #شاشا وقناة #LBCl🔥♥️
@nadinenjeim @Mohamad_kaiss
Clear guidance supports better patient care
The first EHA–Lymphoma Coalition patient-friendly guideline on #LBCL is now available, translating complex recommendations into language your patients can understand and use.
Developed with patient experts, it helps you guide conversations, support understanding, and empower shared decision-making in daily practice.
Read the guideline here: https://t.co/FqYjKqimRL
@knowyournodes
Last Seen Hashtags on Sotwe
ท่าวังผานัดเย็ด
Seen from Thailand
allowflash
Seen from United States
รับงานบางแสน
Seen from Thailand
正装黑袜
Seen from United States
남존여비
Seen from Korea
konyagay
Seen from Turkey
갱뱅(1)
Seen from Korea
anxiouspanda
Seen from Russia
สาวเสียบอุดร
Seen from Thailand
mgai mgai()*+filter:native_video
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers